



B. TECH DEGREE EXAMINATIONS: NOV/DEC 2022

(Regulation 2018)

Seventh Semester

BIOTECHNOLOGY

U18BTE0005 Vaccine Technology

COURSE OUTCOMES

- CO1:** Comprehend knowledge about the historical vaccine development and conventional vaccines in disease prevention
- CO2:** Classify and understand about different bacterial vaccine preparation methods
- CO3:** Acquire fundamental research knowledge to implement the production viral vaccines
- CO4:** Understand advancement of therapeutic vaccines and technological applications
- CO5:** Recognize the fundamental knowledge vaccine production through modern recombinant DNA and vaccine delivery methods
- CO6:** Understand the regulatory issues, guidelines and environmental concerns with the use of recombinant vaccines

Time: Three Hours

Maximum Marks: 100

Answer all the Questions:-

PART A (10 x 2 = 20 Marks)

(Answer not more than 40 words)

- | | | |
|---|-----|-------------------|
| 1. Mention Lady Mary Wortley Montagu's contribution in the field of vaccine research. | CO1 | [K ₂] |
| 2. Expand the following type of vaccine: i).RVV and ii.) PCV . | CO1 | [K ₂] |
| 3. BCG vaccination should only be considered for children who have a negative TB test and who are continually exposed, and cannot be separated from adults- Justify this statement. | CO2 | [K ₄] |
| 4. List any two bacterial components used to prepare acellular pertussis vaccines. | CO2 | [K ₂] |
| 5. Tabulate the main similarity between Europe, Japan, and India for production of different types of rabies vaccine. | CO3 | [K ₂] |
| 6. Tissue culture is a useful method for cultivating clinical samples suspected of harboring a virus- Justify. | CO3 | [K ₃] |
| 7. What are the strategies to be considered while developing a recombinant coronavirus vaccine? | CO4 | [K ₃] |
| 8. State any one salient feature of "Covifenz" vaccine and where it developed? | CO4 | [K ₂] |
| 9. Distinguish vaccinia and variola virus. | CO5 | [K ₃] |
| 10. Categorize recombinant viral vaccines based on their replication ability. | CO5 | [K ₂] |

Answer any FIVE Questions:-
PART B (5 x 16 = 80 Marks)
(Answer not more than 400 words)

- | | | | | | |
|-----|----|---|----|-----|-------------------|
| 11. | a) | Identify the knowledge gap to develop new vaccines by understanding vaccine induced antibody in biological system. | 4 | CO1 | [K ₃] |
| | b) | Tabulate and compare different types of vaccines and their clinical uses – Give an example for each type. | 12 | CO1 | [K ₃] |
| 12. | a) | Analyse the effect of temperature and freezing condition on the final quality/effectiveness of vaccine. | 8 | CO2 | [K ₄] |
| | b) | Illustrate process flow diagram for production of any ONE vaccine with critical steps. | 8 | CO2 | [K ₃] |
| 13. | a) | Narrate various applications of cell culture techniques for vaccine development. | 8 | CO3 | [K ₂] |
| | b) | When you start to establish primary culture for vaccine production, what type of adventitious agents may be noticed with primary cells? Give example for each primary cell. | 8 | CO3 | [K ₃] |
| 14. | a) | Explain any TWO protein based edible vaccines with suitable host plant for synthesis. | 4 | CO4 | [K ₂] |
| | b) | As a clinical pathologist, how will you choose adjuvants for formulation of a vaccine? Give specifications for these adjuvants. | 12 | CO4 | [K ₄] |
| 15. | a) | Compare any two vaccine delivery methods and add a note their limitations. | 4 | CO5 | [K ₃] |
| | b) | Routes of vaccine administration will vary with respect to age and nature of vaccine – Justify this statement with specific examples. | 12 | CO5 | [K ₃] |
| 16. | a) | How is a vaccine approved for mass production and distribution from laboratory scale to industrial scale? | 4 | CO6 | [K ₃] |
| | b) | Illustrate simple process flow diagram for clinical developmental plan, manufacture, packing and storage of vaccine with adequate guidelines. | 12 | CO6 | [K ₃] |
